ArticleMolecular genetics & genomic medicine2026
Implementation of an Inherited Diseases Gene Panel to Accelerate Precision Medicine in the South African Public Healthcare System.
Article in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Characterisation of Treacher Collins Syndrome in a South African Cohort: Novel Disease-Causing Variants in TCOF1 and POLR1D.Molecular genetics & genomic medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundWhile whole genome and exome sequencing is already being implemented in clinics across the globe, there is still very little uptake of these technologies in African healthcare facilities. Significant hurdles remain that impede the translation of these highly effective mutation screening strategies into appropriate and effective clinical services in low- and middle-income countries.
methodsWe developed, validated, and implemented a phenotype-driven genetic testing platform using a 500-gene Ion AmpliSeq Inherited Diseases Panel (IDP) within the South African State healthcare system. This panel enables testing for over 1000 Mendelian disorders using a single laboratory workflow, followed by selective, phenotype-guided analysis to minimize the risk of incidental or secondary findings. A pooled sequencing strategy was used to optimize resource efficiency, achieving an average coverage of 200-400× per sample.
resultsAmong 276 patients tested during the validation phase, a molecular diagnosis was identified in 46% (127/276) of cases. All pathogenic and likely pathogenic variants were submitted to ClinVar to support global data sharing and variant interpretation. The high coverage achieved reduced the need for additional validation testing, supporting the panel's efficiency and reliability in a clinical diagnostic setting. DISCUSSION: This IDP enables us to improve genetic counselling, identify patients with well-described genetic disorders for whom appropriate interventions are needed and/or available and identify patients that would benefit from whole exome or genome-based testing, and allow for risk clarification for close relatives. This system has laid the foundation for rare disease genetic testing in the South African public healthcare system and can be used as a point of departure for genetic service implementation in resource-constrained environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.